The scientific report from the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures performed in the eastern part of Central Europe.

Maciej Nowacki, Wojciech Zegarski
Author Information
  1. Maciej Nowacki: Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
  2. Wojciech Zegarski: Department of Surgical Oncology, Ludwik Rydygier's Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.

Abstract

Objective To perform a single-centre, detailed analysis of the preparations for the introduction of the first pressurized intraperitoneal aerosol chemotherapy (PIPAC) programme in the eastern part of Central Europe. Methods The study analysed the 14-month preparation period prior to the performance of the first PIPAC procedure with respect to: (i) general preparations; (ii) patient referral and qualification; (iii) the first PIPAC procedure; (iv) the 2 weeks following PIPAC programme establishment; and (v) general problematic issues that arose. Results The length of time needed to prepare our institution for the first PIPAC procedure was extremely long compared with other European Union PIPAC centres: 14 months versus a standard 3-6 months of preparation. The longest amount of time (12 months) was required to prepare the required paperwork. Conclusions A new PIPAC programme was successfully established in the eastern part of Central Europe. The length of time to implement this method was significantly longer because of lengthy bureaucratic processes. These current findings should help new centres, especially in this part of Europe, to establish a PIPAC programme more quickly.

Keywords

References

  1. Clin Exp Metastasis. 2017 Jun;34(5):309-314 [PMID: 28516306]
  2. Ann Surg. 2016 Oct;264(4):640-9 [PMID: 27433907]
  3. Colorectal Dis. 2016 Apr;18(4):364-71 [PMID: 26400556]
  4. Int J Hyperthermia. 2017 Aug;33(5):528-533 [PMID: 28540833]
  5. Minerva Chir. 2014 Feb;69(1):27-35 [PMID: 24675244]
  6. Eur J Surg Oncol. 2017 Jun;43(6):1102-1109 [PMID: 28431896]
  7. Lancet Oncol. 2004 Apr;5(4):219-28 [PMID: 15050953]
  8. J Cancer Surviv. 2017 Dec;11(6):808-821 [PMID: 28601981]
  9. World J Surg Oncol. 2016 Apr 29;14:128 [PMID: 27125996]
  10. Eur J Vasc Endovasc Surg. 2008 Sep;36(3):253-7 [PMID: 18586534]
  11. World J Gastroenterol. 2014 Oct 21;20(39):14371-80 [PMID: 25339824]
  12. BMC Cancer. 2017 Jan 6;17(1):26 [PMID: 28061769]
  13. Lancet Oncol. 2016 Dec;17(12):1709-1719 [PMID: 27743922]
  14. Ann Surg Oncol. 2013 Oct;20(11):3504-11 [PMID: 23765417]
  15. Br J Surg. 2017 May;104(6):669-678 [PMID: 28407227]
  16. J Gastrointest Oncol. 2016 Feb;7(1):18-28 [PMID: 26941981]
  17. Biomed Res Int. 2016;2016:2505601 [PMID: 27803921]
  18. Int J Surg Oncol. 2014;2014:912418 [PMID: 24693422]
  19. Clin Exp Metastasis. 2017 Jun;34(5):291-293 [PMID: 28593512]
  20. Int J Surg Oncol. 2016;2016:2495131 [PMID: 27006828]
  21. Oncotarget. 2015 Sep 8;6(26):22776-98 [PMID: 26254295]
  22. Anticancer Res. 2015 Dec;35(12):6723-9 [PMID: 26637888]
  23. World J Gastrointest Oncol. 2010 Feb 15;2(2):98-101 [PMID: 21160927]
  24. World J Gastroenterol. 2016 Aug 14;22(30):6906-16 [PMID: 27570426]
  25. Jpn J Clin Oncol. 2001 Dec;31(12):571-2 [PMID: 11902486]
  26. World J Gastroenterol. 2012 Oct 21;18(39):5489-94 [PMID: 23112540]
  27. Ugeskr Laeger. 2016 May 23;178(21): [PMID: 27237925]
  28. Arch Med Sci. 2016 Oct 1;12(5):1158-1173 [PMID: 27695507]
  29. World J Surg Oncol. 2016 Sep 27;14(1):253 [PMID: 27678344]
  30. Cancer. 2000 Jun 1;88(11):2512-9 [PMID: 10861427]
  31. P T. 2008 Oct;33(10):607-8 [PMID: 19750043]
  32. Gastroenterol Res Pract. 2017;2017:4596176 [PMID: 28316621]
  33. Eur J Epidemiol. 2016 Mar;31(3):217-28 [PMID: 26968840]
  34. Pleura Peritoneum. 2017 Jun 1;2(2):43-45 [PMID: 30911632]
  35. Int J Hyperthermia. 2017 Aug;33(5):520-527 [PMID: 28540827]
  36. J Gastrointest Surg. 2016 Feb;20(2):367-73 [PMID: 26511950]
  37. Surg Endosc. 2010 Jul;24(7):1594-615 [PMID: 20054575]
  38. Pan Afr Med J. 2011;9:20 [PMID: 22355430]
  39. J Cancer. 2016 Jul 21;7(12):1621-1631 [PMID: 27698899]
  40. Am Health Drug Benefits. 2015 Jun;8(4):196-9 [PMID: 26157541]

MeSH Term

Administration, Topical
Aerosols
Aged
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Doxorubicin
Drug Approval
Environment, Controlled
Female
Humans
Infusions, Parenteral
Laparoscopy
Learning Curve
Male
Middle Aged
Operating Rooms
Patient Care Team
Patient Selection
Peritoneal Neoplasms
Poland
Pressure
Program Development
Retrospective Studies
Stomach Neoplasms
Surgical Oncology
Time Factors

Chemicals

Aerosols
Doxorubicin
Cisplatin

Word Cloud

Created with Highcharts 10.0.0PIPACfirstprogrammepartEuropeintraperitonealchemotherapyeasternCentralproceduretimemonthspreparationspressurizedaerosolpreparationgenerallengthpreparerequirednewObjectiveperformsingle-centredetailedanalysisintroductionMethodsstudyanalysed14-monthperiodpriorperformancerespectto:iipatientreferralqualificationiiiiv2weeksfollowingestablishmentvproblematicissuesaroseResultsneededinstitutionextremelylongcomparedEuropeanUnioncentres:14versusstandard3-6longestamount12paperworkConclusionssuccessfullyestablishedimplementmethodsignificantlylongerlengthybureaucraticprocessescurrentfindingshelpcentresespeciallyestablishquicklyscientificreportproceduresperformeddrugdeliveryperitonealcarcinomatosissurgicaloncology

Similar Articles

Cited By